Kamada (KMDA)
NASDAQ:KMDA
Kamada Stock Analysis & Ratings
298 Followers
KMDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.22 - $6.96
Previous Close$5.43
Volume10.16K
Average Volume (3M)20.14K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-36.1
Beta0.68
Next EarningsAug 17, 2022
EPS Forecast-$0.02
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$11.00
Smart Score4
EPS (TTM)-0.15
Shares Outstanding44,800,504
R-Squared0.20
Standard Deviation0.10
10 Day Avg. Volume34,753
30 Day Avg. Volume20,137
P/B Ratio1.25
P/S Ratio2.65
P/CF Ratio29.00
P/FCF Ratio-2.20
Total Debt$4.49M
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside109.13% Upside
Rating ConsensusModerate Buy
Alpha-0.00798
Number of Analyst Covering1
Kamada News
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was $4.22 and its highest was $6.96 in the past 12 months.
What is Kamada’s market cap?
Currently, no data Available
What is Kamada’s price target?
The average price target for Kamada is $11.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $11.00 ,the lowest forecast is $11.00. The average price target represents 109.13% Increase from the current price of $5.26.
The highest analyst price target is $11.00 ,the lowest forecast is $11.00. The average price target represents 109.13% Increase from the current price of $5.26.
What do analysts say about Kamada?
Kamada’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is Aug 17, 2022 which is today.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on May 17, 2022. The company reported -$0.037 earnings per share for the quarter, missing the consensus estimate of $0.03 by -$0.067.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada does not currently pay dividends.
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is -$0.02.
How many shares outstanding does Kamada have?
Kamada has 44,799,793 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of -$0.037 in its last earnings report, missing expectations of $0.03. Following the earnings report the stock price went up 3.789%.
Which hedge fund is a major shareholder of Kamada?
Among the largest hedge funds holding Kamada’s share is ARK Investment Management LLC. It holds Kamada’s shares valued at 2M.
---
Kamada Stock Analysis
Smart ScoreNeutral
1
2
3
4
5
6
7
8
9
10
Analyst Forecast
Moderate Buy
Average Price Target: $11.00
Blogger Sentiment
N/A
Currently Not Enough Data Available
Hedge Fund Holdings
▼ Decreased
By 22.1K Shares Last Quarter.
Insider Transactions
N/A
Currently Not Enough Data Available
Retail Investors
Very Negative
Last 7 Days ▼ 0.8% Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish 50% Bearish 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.73%
12-Months-Change
Fundamentals
Return on Equity
-3.79%
Trailing 12-Months
Asset Growth
43.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kamada
Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the Proprietary Products segment and the Distribution segment. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the supply of plasma-based products for clinical use. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.
---
Urogen Pharma
―
Gamida Cell
―
Enlivex Therapeutics
―
Collplant Holdings
―
GlaxoSmithKline
―
---